Login to Your Account

Pharma: Clinic roundup

Monday, May 12, 2014
Pfizer Inc., of New York, reported results from two phase II studies of bivalent rLP2086, its recombinant vaccine candidate in development for the prevention of invasive meningococcal disease caused by Neisseria meningitides serogroup B in subjects ages 10 to 25.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription